Baseline characteristics
| Characteristic . | All patients (N = 334) . | Intercalated (n = 204) . | EOT (n = 130) . | P . |
|---|---|---|---|---|
| Age, median (range), y | 61 (20-82) | 60 (20-81) | 62 (20-82) | .78 |
| Male sex | 197 (59) | 116 (57) | 81 (62) | .32 |
| Creatinine clearance, median (range), mL/min | 111 (44-299) | 115 (45-299) | 107 (44-236) | .03* |
| Advanced stage | 266 (82) | 168 (82) | 107 (82) | .99 |
| Elevated LDH | 242 (72) | 143 (70) | 99 (76) | .33 |
| ECOG PS ≥2 | 88 (27) | 45 (22) | 44 (34) | .02* |
| 1 EN site | 123 (37) | 81 (40) | 42 (32) | .38 |
| 2 EN sites | 116 (35) | 66 (32) | 50 (38) | |
| ≥3 EN sites | 90 (27) | 55 (27) | 35 (27) | |
| Renal/adrenal involvement | 55 (16) | 26 (13) | 29 (22) | .02* |
| “Double hit”† | 10 (3) | 5 (3) | 5 (4) | .65 |
| CNS-IPI | ||||
| Low (0-1) | 51 (16) | 32 (16) | 19 (15) | |
| Intermediate (2-3) | 123 (35) | 88 (45) | 35 (27) | |
| High (4-6) | 151 (46) | 77 (39) | 74 (58) | <.001* |
| IT prophylaxis | 142 (42) | 69 (34) | 73 (56) | <.001* |
| Received 6 cycles of R-CHOP | 319 (96) | 194 (95) | 125 (96) | .65 |
| No. HD-MTX received, median (range) | 2 (1-4) | 2 (1-4) | 2 (1-3) | .62 |
| Received ≥3 g/m2 HD-MTX | 309 (93) | 191 (94) | 118 (91) | .33 |
| Characteristic . | All patients (N = 334) . | Intercalated (n = 204) . | EOT (n = 130) . | P . |
|---|---|---|---|---|
| Age, median (range), y | 61 (20-82) | 60 (20-81) | 62 (20-82) | .78 |
| Male sex | 197 (59) | 116 (57) | 81 (62) | .32 |
| Creatinine clearance, median (range), mL/min | 111 (44-299) | 115 (45-299) | 107 (44-236) | .03* |
| Advanced stage | 266 (82) | 168 (82) | 107 (82) | .99 |
| Elevated LDH | 242 (72) | 143 (70) | 99 (76) | .33 |
| ECOG PS ≥2 | 88 (27) | 45 (22) | 44 (34) | .02* |
| 1 EN site | 123 (37) | 81 (40) | 42 (32) | .38 |
| 2 EN sites | 116 (35) | 66 (32) | 50 (38) | |
| ≥3 EN sites | 90 (27) | 55 (27) | 35 (27) | |
| Renal/adrenal involvement | 55 (16) | 26 (13) | 29 (22) | .02* |
| “Double hit”† | 10 (3) | 5 (3) | 5 (4) | .65 |
| CNS-IPI | ||||
| Low (0-1) | 51 (16) | 32 (16) | 19 (15) | |
| Intermediate (2-3) | 123 (35) | 88 (45) | 35 (27) | |
| High (4-6) | 151 (46) | 77 (39) | 74 (58) | <.001* |
| IT prophylaxis | 142 (42) | 69 (34) | 73 (56) | <.001* |
| Received 6 cycles of R-CHOP | 319 (96) | 194 (95) | 125 (96) | .65 |
| No. HD-MTX received, median (range) | 2 (1-4) | 2 (1-4) | 2 (1-3) | .62 |
| Received ≥3 g/m2 HD-MTX | 309 (93) | 191 (94) | 118 (91) | .33 |
Data are n (%) unless otherwise noted. Missing data: LDH, n = 8; PS, n = 3; Renal/adrenal involvement, n = 2; Double hit, n = 38; CNS-IPI, n = 9. ECOG PS, Eastern Cooperative Oncology Group performance status; EN, extranodal; IT, intrathecal.
Statistically significant.
Presence of MYC with BCL2 and/or BCL6 translocations.